TY - JOUR T1 - A year of COVID-19 GWAS results from the GRASP portal reveals potential SARS-CoV-2 modifiers JF - medRxiv DO - 10.1101/2021.06.08.21258507 SP - 2021.06.08.21258507 AU - Florian Thibord AU - Melissa V. Chan AU - Ming-Huei Chen AU - Andrew D. Johnson Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/06/11/2021.06.08.21258507.abstract N2 - Host genetic variants influence the susceptibility and severity of several infectious diseases, and the discovery of novel genetic associations with Covid-19 phenotypes could help developing new therapeutic strategies to reduce its burden.Between May 2020 and February 2021, we used Covid-19 data released periodically by UK Biobank and performed over 400 Genome-Wide Association Studies (GWAS) of Covid-19 susceptibility (N=15,738 cases), hospitalization (N=1,916), severe outcomes (N=935) and death (N=828), stratified by ancestry and sex.In coherence with previous studies, we observed 2 independent signals at the chr3p21.31 locus (rs73062389-A, OR=1.22, P=7.64×10−14 and rs13092887-A, OR=1.73, P=2.38×10−8, in Europeans) modulating susceptibility and severity, respectively, and a signal influencing susceptibility at the ABO locus (rs9411378-A, OR=1.10, P =7.36×10−10, in Europeans), which was more significant in men than in women (P=0.01). In addition, we detected 7 genome-wide significant signals in the last data release analyzed (on February 24th 2021), of which 4 were associated with susceptibility (SCRT2, LRMDA, chr15q24.2, MIR3681HG), 2 with hospitalization (ANKS1A, chr12p13.31) and 1 for severity (ADGRE1). Finally, we identified over 300 associations which increased in significance over time, and reached at least P<10−5 in the last data release analyzed. We replicated 2 of these signals in an independent dataset: a variant downstream of CCL3 (rs2011959) associated with severity in men, and a variant located in an ATP5PO intron (rs12482569) associated with hospitalization.These results, freely available on the GRASP portal, provide new insights on the host genetic architecture of Covid-19 phenotypes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAll authors were supported by NIH Intramural Research Program funds. The views expressed in this manuscript are those of the authors and do not necessarily represent the views of the National Heart, Lung, and Blood Institute; the National Institutes of Health; or the U.S. Department of Health and Human Services. This research has been conducted using the UK Biobank Resource under Application Number 28525. UK Biobank was established by the Wellcome Trust, Medical Research Council, Department of Health, Scottish government, and Northwest Regional Development Agency. It has also had funding from the Welsh assembly government and the British Heart Foundation. All UKB analyses for this manuscript were conducted on the NIH Biowulf high performance computing cluster (https://hpc.nih.gov/). The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK Biobank obtained ethical approval for this study by the North West Multicenter Research Ethics Committee. All participants gave written informed consent to participate and be followed up. This research has been conducted using the UK Biobank Resource under Application Number 28525.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during this study are available at the GRASP Covid-19 portal https://grasp.nhlbi.nih.gov/Covid19GWASResults.aspx ER -